NeuroRx and Relief Therapeutics announce fast track designation granted by the FDA to RLF-100 (aviptadil) for the treatment of respiratory distress in COVID-19

NeuroRx

24 June 2020 - At the FDA’s request, NeuroRx is submitting an expanded access policy enabling physicians to request RLF-100 for patients who meet the criteria.

NeuroRx, in partnership with Relief Therapeutics today announced that the U.S. FDA awarded fast track designation to NeuroRx for the investigation of RLF-100 (aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19. 

RLF-100 is a synthetic form of human vasoactive intestinal peptide which reduces inflammation in the lungs and protects the alveolar type II cells that are believed to be an entry route for the SARS-CoV-2 to invade the lungs.

Read NeuroRx press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track , COVID-19